
Baijin Life Science Holdings Limited, together with its subsidiaries, engages in the procurement, processing, design, production, and wholesale distribution of pearls and fine jewelry products in Hong Kong, the People’s Republic of China, the United States, and internationally. It operates through three segments: Jewellery Business, Skincare Business, and Strategic Investment. The company is involved in the research and development of cellular and large molecule drugs; clinical research services; research, development, and sale of medical devices, cosmetics, and private care products under the FO brand name; and provision of scientific research, franchise licensing, and consultation services. It also engages in real estate financial assets investments; provision of skincare services; and supply chain management.